Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 4:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 348 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Higher Risk Myelodysplastic Syndrome Clear all
Terminated Phase 2Phase 3 Interventional

Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS)

NCT00038805
View directory record Official record
Conditions
Leukemia
Interventions
Mylotarg
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
55 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Oct 2, 2026, 4:20 PM EDT
Active, not recruiting Phase 1 Interventional

PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS

NCT03927261
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
PRGN-3006 T Cells
Drug
Lead sponsor
Precigen, Inc
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Tampa, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 8, 2024 · Synced Oct 2, 2026, 4:20 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

NCT04068597
View directory record Official record
Conditions
Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma, Higher-risk Myelodysplastic Syndrome, Peripheral T Cell Lymphoma
Interventions
CCS1477, Pomalidomide, Dexamethasone, Azacitidine, Venetoclax, Bortezomib, Ixazomib, Elranatamab, Teclistamab, Lenalidomide, Daratumumab
Drug
Lead sponsor
CellCentric Ltd.
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
6
States / cities
Atlanta, Georgia • Indianapolis, Indiana • Bethesda, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 2, 2026, 4:20 PM EDT
Completed Phase 2 Interventional Results available

Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies

NCT00566696
View directory record Official record
Conditions
Leukemia, Acute Lymphocytic (ALL), Leukemia, Myeloid, Acute(AML), Leukemia, Myeloid, Chronic(CML), Juvenile Myelomonocytic Leukemia (JMML), Hemoglobinuria, Paroxysmal Nocturnal (PNH), Hodgkin Lymphoma, Lymphoma, Non-Hodgkin (NHL), Myelodysplastic Syndrome (MDS)
Interventions
CliniMACS, Stem cell transplantation, Fludarabine, Thioplex®, L-phenylalanine mustard, Mycophenolate mofetil, Rituxan™, Alemtuzumab, Cyclophosphamide, Anti-thymocyte globulin (Rabbit), G-CSF, Muromonab
Device · Procedure · Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 14, 2020 · Synced Oct 2, 2026, 4:20 PM EDT
Completed Phase 2 Interventional Results available

Omacetaxine in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) Failure

NCT02159872
View directory record Official record
Conditions
Leukemia
Interventions
Omacetaxine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 2, 2026, 4:20 PM EDT
Completed Phase 2 Interventional Results available

Allo vs Hypomethylating/Best Supportive Care in MDS (BMTCTN1102)

NCT02016781
View directory record Official record
Conditions
MDS
Interventions
Allogeneic Hematopoietic Cell Transplant, Hypomethylating Therapy / Best Supportive Care
Procedure
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
50 Years to 75 Years
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
37
States / cities
Duarte, California • Stanford, California • Gainesville, Florida + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2023 · Synced Oct 2, 2026, 4:20 PM EDT
Recruiting Phase 1 Interventional

A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes

NCT06146257
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
GLB-001
Drug
Lead sponsor
GluBio Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
8
States / cities
Duarte, California • Irvine, California • Kansas City, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 2, 2026, 4:20 PM EDT
Not yet recruiting Phase 1 Interventional

Study of Monzosertib In Patients With R/R AML Or High-Risk Myelodysplastic Syndrome

NCT07780565
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome
Interventions
Monzosertib, Posaconazole, Isavuconazole
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 2, 2026, 4:20 PM EDT
Completed Phase 2 Interventional Results available

Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies

NCT00795132
View directory record Official record
Conditions
Acute Leukaemia, Chronic Disease, Leukemia, Myelodysplasia, Lymphoma
Interventions
Busulfan, Anti-Thymocyte Globulin, Fludarabine, Cyclosporine, Mycophenolate mofetil
Drug
Lead sponsor
University of Utah
Other
Eligibility
Up to 21 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Oct 2, 2026, 4:20 PM EDT
Terminated Phase 2 Interventional Results available

Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

NCT00818649
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndrome
Interventions
bortezomib, vorinostat
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 2, 2026, 4:20 PM EDT
Completed Phase 2 Interventional Results available

CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT02019069
View directory record Official record
Conditions
Adult Acute Erythroid Leukemia (M6), Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes
Interventions
liposomal cytarabine-daunorubicin CPX-351
Drug
Lead sponsor
Rondeep Brar
Other
Eligibility
60 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Oct 2, 2026, 4:20 PM EDT
Completed Phase 2 Interventional

Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDS

NCT00195000
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Mylotarg, Cytarabine
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
60 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 2, 2026, 4:20 PM EDT
Terminated Phase 1 Interventional Results available

Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML

NCT05275439
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
SL-172154, Azacitidine (AZA), Venetoclax
Drug
Lead sponsor
Shattuck Labs, Inc.
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
16
States / cities
Duarte, California • Los Angeles, California • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 2, 2026, 4:20 PM EDT
Terminated Phase 2 Interventional

Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia

NCT00066417
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic/Myeloproliferative Diseases
Interventions
cyclophosphamide, cyclosporine, fludarabine phosphate, methylprednisolone, therapeutic allogeneic lymphocytes, thiotepa, allogeneic bone marrow transplantation, biological therapy, bone marrow ablation with stem cell support, bone marrow transplantation, chemotherapy, leukocyte therapy, non-specific immune-modulator therapy, peripheral blood lymphocyte therapy, peripheral blood stem cell transplantation, radiation therapy
Drug · Procedure
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
10 Years to 50 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 1, 2013 · Synced Oct 2, 2026, 4:20 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety, Clinical Activity, Pharmacokinetics (PK) and Pharmacodynamics Study of GSK2879552, Alone or With Azacitidine, in Subjects With High Risk Myelodysplastic Syndromes (MDS)

NCT02929498
View directory record Official record
Conditions
Myelodysplastic Syndrome, Myelodysplastic Syndromes
Interventions
GSK2879552, Azacitidine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
4
States / cities
Augusta, Georgia • Durham, North Carolina • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Oct 2, 2026, 4:20 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies

NCT01682226
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndrome, Lymphoma
Interventions
CliniMACS Fractionation system (Arm A), CliniMACS Fractionation system (Arm B), Haploidentical donor CD34+ cells
Device · Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
2 Years to 70 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 5, 2022 · Synced Oct 2, 2026, 4:20 PM EDT
Active, not recruiting Phase 1 Interventional

Hu8F4 in Treating Patients With Advanced Hematologic Malignancies

NCT02530034
View directory record Official record
Conditions
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid Cell Neoplasm, High Risk Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts-1, Myelodysplastic Syndrome With Excess Blasts-2, Myelofibrosis, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia, Secondary Acute Myeloid Leukemia
Interventions
Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
4
States / cities
Augusta, Georgia • The Bronx, New York • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 2, 2026, 4:20 PM EDT
Terminated Phase 1 Interventional

A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02)

NCT04417517
View directory record Official record
Conditions
Higher Risk Myelodysplastic Syndromes
Interventions
evorpacept, azacitidine
Drug
Lead sponsor
ALX Oncology Inc.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
10
States / cities
Los Angeles, California • Chicago, Illinois • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Oct 2, 2026, 4:20 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

NCT00656617
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Interventions
Idarubicin, Cytarabine, Vorinostat
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years to 65 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2015 · Synced Oct 2, 2026, 4:20 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)

NCT02152956
View directory record Official record
Conditions
AML
Interventions
Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off, Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off, Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off, Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off, Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose, Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose, Flotetuzumab 500 ng/kg/day, continuous infusion, after multi-step lead-in dose, Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multi-step lead-in dose, Flotetuzumab 700 ng/kg/day, continuous infusion, after multi-step lead-in dose, Ruxolitinib, Flotetuzumab 300 ng/kg/day, continuous infusion, after multi-step lead-in dose
Biological · Drug
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
20
States / cities
Duarte, California • La Jolla, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 2, 2026, 4:20 PM EDT
Recruiting Phase 1Phase 2 Interventional

Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

NCT04047641
View directory record Official record
Conditions
Acute Myeloid Leukemia, Blasts 20 Percent or More of Bone Marrow Nucleated Cells, High Risk Myelodysplastic Syndrome, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent High Risk Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory High Risk Myelodysplastic Syndrome
Interventions
Cladribine, Cytarabine, Idarubicin, Quizartinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 2, 2026, 4:20 PM EDT
Suspended Phase 1 Interventional

A Study Evaluating the Safety and Efficacy of IBI188 in Combination With AZA in Subjects With Newly Diagnosed MDS

NCT04511975
View directory record Official record
Conditions
MDS
Interventions
IBI188, Azacitidine
Drug
Lead sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Bethesda, Maryland • Brick, New Jersey • Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Oct 2, 2026, 4:20 PM EDT
Active, not recruiting Not applicable Interventional

Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS

NCT04482894
View directory record Official record
Conditions
Leukemia, Acute, AML, Adult, ALL, Adult, Myelodysplastic Syndromes
Interventions
Palliative Care Visits
Other
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 2, 2026, 4:20 PM EDT
Terminated Phase 1Phase 2 Interventional

Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional Cytarabine

NCT00655395
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Interventions
Laromustine (VNP40101M) and Ara-C
Drug
Lead sponsor
Viron Therapeutics Inc
Industry
Eligibility
60 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 28, 2019 · Synced Oct 2, 2026, 4:20 PM EDT